BPC-157

BPC-157 is a synthetic peptide of 15 amino acids (a "pentadecapeptide," sequence GEPPPGKPADDAGLV) based on a fragment of a protective protein found in human gastric juice — the name stands for "Body Protection Compound." It was developed by Predrag Sikirić's group at the University of Zagreb and has been studied in animals since the early 1990s, mostly in models of injury to tendons, ligaments, muscle, and the gastrointestinal tract.

Evidence tier: preclinical. BPC-157 has one of the widest gaps in the peptide world between the size of its animal literature and the size of its human literature. Hundreds of rodent studies report accelerated healing across a striking range of tissues — yet no peer-reviewed human randomized controlled trial results have ever been published. A 2025 literature and patent review concluded flatly that "there are no completed clinical studies describing its efficacy in humans," noting that a Phase I trial begun in 2015 in 42 healthy volunteers ended with the sponsors cancelling submission of the results in 2016 (Józwiak et al., Pharmaceuticals 2025). Everything else on this page should be read through that lens.

BPC-157 has no confirmed receptor, and its mechanism in humans is unknown. The proposed mechanisms come from animal and cell-culture work:

• Angiogenesis: in rat aortic-ring and hindlimb-ischemia models, BPC-157's pro-angiogenic effect was associated with activation and up-regulation of the VEGFR2 receptor (Hsieh et al., J Mol Med 2017).

• Tendon-cell behavior: in cultured rat tendon fibroblasts, BPC-157 accelerated explant outgrowth, improved cell survival under oxidative stress, and increased migration dose-dependently via the FAK–paxillin pathway (Chang et al., J Appl Physiol 2011).

• Cytoprotection and the gut–brain axis: the Zagreb group frames BPC-157 as a "cytoprotective" mediator that stabilizes gastrointestinal mucosa and interacts with nitric-oxide, dopamine, and serotonin systems (Sikiric et al., Curr Neuropharmacol 2016).

One structural caveat: a large share of the literature comes from a single research network in Zagreb. Independent groups (in Taiwan and Türkiye, among others) have reproduced some tendon and angiogenesis findings, but independent replication remains thinner than the total paper count suggests.

BPC-157 has no approved indication anywhere. It is not an approved drug in the United States, Europe, or any other major jurisdiction, and it has no established medical use. In practice it circulates in three contexts: academic animal research, "research chemical" vendors selling to consumers under not-for-human-use labeling, and (formerly) compounding pharmacies — a route the FDA has effectively closed by naming BPC-157 on its list of bulk substances that may present significant safety risks when used in compounding.

Discussion of BPC-157 among athletes and in recovery communities centers on tendon, ligament, muscle, and gut complaints — the same territory as the rodent models. The distinction that matters: those models are hypothesis-generating research, not evidence that the same doses, routes, or effects apply to people.

BPC-157 is named explicitly as an example in category S0 of the WADA Prohibited List, which covers pharmacological substances with no current approval by any governmental health authority for human therapeutic use. S0 substances are prohibited at all times — in and out of competition — and USADA has published a dedicated athlete warning about BPC-157.

Real sanctions have followed, and the case details matter more than the list itself:

• Emma Brooks (volleyball): a Canadian U SPORTS athlete sanctioned for four years in 2025 by the Canadian Centre for Ethics in Sport for use of BPC-157 and TB-500, with ineligibility running to December 2028 (Sport Integrity Canada).

• Anthony McCauley (triathlon): accepted a USADA sanction in 2025 after a whistleblower-triggered investigation found he possessed and used BPC-157 and TB-500 — and additionally promoted prohibited peptides to followers on social media, which USADA treated as attempted complicity (USADA announcement).

• Kamryn Lute (speed skating): received a one-year sanction beginning April 2024 after using a supplement containing BPC-157 that had been recommended by a medical provider. She never tested positive — she declared the supplement and admitted use during the investigation, and an independent arbitrator imposed the ban anyway (USADA announcement).

• Cortney Casey (MMA): accepted a four-month suspension in 2023 under the UFC anti-doping program after using BPC-157 that had been prescribed and provided by a doctor for a medical condition (USADA announcement).

Two lessons recur across these cases: a positive test is not required for a violation (declared or admitted use is enough), and "my doctor recommended it" is not a defense.

The honest answer on BPC-157 safety is that nobody has the data. The FDA's compounding safety-risk entry states that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration," has "complexities with regard to peptide-related impurities," and that the agency "has identified no, or only limited, safety-related information for the proposed routes of administration" — meaning FDA lacks sufficient information to know whether it would cause harm in humans (FDA bulk drug substances list).

What can be said concretely:

• Animal studies generally report no obvious toxicity at the doses tested, but formal toxicology adequate for human use has never been published (Józwiak et al. 2025).

• Informal user reports mention injection-site irritation, nausea, headache, and dizziness. None of this has been systematically collected, so frequency and causality are unknown.

• Because BPC-157 promotes blood-vessel growth in animal models, a theoretical concern is behavior around existing tumors. No study has shown BPC-157 causes cancer — but no study has been designed to rule it out.

• Products sold online are unregulated; identity, purity, sterility, and actual peptide content are not verified by any authority.

For general context on evaluating experimental compounds, see what are the risks of peptides and who should avoid using peptides.

No human dose of BPC-157 has ever been established, because no human dose-finding study has ever been published. Human pharmacokinetics — absorption, half-life, distribution — are simply not characterized in the peer-reviewed literature (Józwiak et al. 2025). The peptide is often described as stable in gastric juice, and some rodent studies achieved effects with oral dosing in drinking water as well as by injection (Cerovecki et al., J Orthop Res 2010).

Vials are supplied as lyophilized powder for reconstitution with bacteriostatic water; the delivered amount depends entirely on the dilution. Our dosing education page covers the reported patterns and where the numbers come from in more depth.

BPC-157 is sold as lyophilized powder for injection, as capsules marketed for gut targets (sometimes as an "arginate salt" claimed to improve stability), and increasingly in blends. The most common pairing is with TB-500, a thymosin beta-4 fragment with its own animal-healing literature and its own WADA prohibition.

The one head-to-head animal study is worth knowing: a 2026 rat Achilles-tendon trial comparing BPC-157 (10 mcg/kg/day), TB-500 (60 mcg/kg/day), and the combination found that TB-500 produced statistically significant improvements in load-to-failure and tendon histology, while BPC-157's improvements were numerical but did not reach significance on total scores — and the combination showed no synergy over either alone (Biçer et al., Jt Dis Relat Surg 2026). See the full BPC-157 vs TB-500 comparison.

The animal literature is genuinely broad. Representative, verifiable studies:

• Transected rat Achilles tendon: BPC-157 improved load-bearing, tensile strength, functional index scores, and collagen organization versus controls (Staresinic et al., J Orthop Res 2003).

• Tendon-to-bone healing: in rat Achilles detachment, BPC-157 promoted reattachment healing and counteracted the impairment caused by corticosteroids (Krivic et al., J Orthop Res 2006).

• Ligament healing: in transected rat medial collateral ligament followed for 90 days, BPC-157 improved functional, biomechanical, and histological outcomes whether given by injection, orally in drinking water, or topically (Cerovecki et al., J Orthop Res 2010).

• Nervous system models: a review compiles rodent findings in stroke, spinal-cord compression, and neurotransmitter-system models (Vukojević et al., Neural Regen Res 2021).

The human side is nearly empty. The most-cited "human study" is a retrospective, uncontrolled case series of intra-articular BPC-157 injections for knee pain from a single clinic (Lee & Padgett, Altern Ther Health Med 2021) — a design that cannot establish efficacy. A 2026 review in the American Journal of Sports Medicine reached the field's consensus conclusion: BPC-157's tendon and muscle findings are "largely unvalidated in human trials," and clinicians should understand the current lack of evidence supporting clinical use (Mayfield et al., Am J Sports Med 2026).

For a study-by-study walkthrough, see the BPC-157 research and evidence page.

• BPC-157 potential benefits and areas of research
• BPC-157 side effects and safety context
• BPC-157 dosing education
• BPC-157 research and evidence overview
• BPC-157 vs TB-500 comparison
• TB-500 overview

Is BPC-157 FDA approved? No. BPC-157 is not approved by the FDA or any other national regulator for any use. The FDA has additionally flagged it on its compounding safety-risk list, stating it has "no, or only limited, safety-related information."

Is BPC-157 legal? It occupies a gray zone. It is not a scheduled controlled substance in the US, but it cannot legally be sold as a drug or dietary supplement for human use, and pharmacy compounding is off the table after the FDA's safety-risk listing. Vendors sell it as a "research chemical" labeled not for human consumption — labeling that shifts legal risk without changing what buyers do with it.

Is BPC-157 banned in sports? Yes, at all times. It is named explicitly in category S0 of the WADA Prohibited List, and athletes have been sanctioned for one to four years — including cases with no positive test, based only on declared or admitted use.

Does BPC-157 actually work in humans? Unknown. The animal evidence is extensive and consistently positive; the published human evidence consists of essentially one uncontrolled case series. No human randomized controlled trial results have been published, and a Phase I trial started in 2015 never reported results (Józwiak et al. 2025).

Is oral BPC-157 as good as injectable? Nobody knows in humans, because no human comparison exists. The peptide is described as stable in gastric juice, and rodent studies have shown effects from oral dosing in some models (Cerovecki et al. 2010), which is more oral plausibility than most peptides have — but it is not evidence of equivalence in people.

How is BPC-157 different from TB-500? Both are unapproved, WADA-prohibited peptides with animal-healing literatures. BPC-157 is a gastric-juice-derived pentadecapeptide; TB-500 is a fragment of thymosin beta-4, an actin-binding protein. In the one head-to-head rat tendon study, TB-500 performed at least as well or better (Biçer et al. 2026). Full breakdown: BPC-157 vs TB-500.

Is BPC-157 safe? There is no adequate human safety dataset — that is the FDA's own position. Animal studies report little toxicity, but immunogenicity, long-term effects, and product-quality risks in the unregulated market are uncharacterized.